Treatment response to Janus kinase inhibitor in a child affected by Aicardi-Goutières syndrome.
Aicardi‐Goutières syndrome
JAK‐inhibitors
baricitinib
neurodevelopmental outcome
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
08
05
2023
revised:
14
06
2023
accepted:
09
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Baricitinib, a Janus kinase inhibitor (JAK-inhibitor), seems to contribute to an improvement of a child affected by Aicardi-Goutières syndrome (AGS), reducing the interferon score and determining a recovery of cognitive, communicative, and relational dysfunctions, while the gross motor deficit persisted. We report the treatment response to baricitinib, a JAK-inhibitor, in a 4-year-old girl affected by Aicardi-Goutières syndrome (AGS2,
Identifiants
pubmed: 37534202
doi: 10.1002/ccr3.7724
pii: CCR37724
pmc: PMC10390657
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7724Informations de copyright
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Front Pediatr. 2021 Oct 27;9:725868
pubmed: 34778129
J Clin Immunol. 2023 Aug;43(6):1436-1447
pubmed: 37171742
Medicine (Baltimore). 2018 Dec;97(52):e13893
pubmed: 30593198
Neurology. 2018 Feb 6;90(6):289-291
pubmed: 29321238
J Clin Med. 2019 May 26;8(5):
pubmed: 31130681
N Engl J Med. 2020 Sep 3;383(10):986-989
pubmed: 32877590
Ann Rheum Dis. 2022 May;81(5):601-613
pubmed: 35086813
Dev Med Child Neurol. 2020 Jan;62(1):42-47
pubmed: 31175662
J Clin Immunol. 2016 Oct;36(7):693-9
pubmed: 27539236
J Child Neurol. 2020 Jan;35(1):7-16
pubmed: 31559893
Expert Rev Clin Immunol. 2020 Feb;16(2):189-198
pubmed: 31855085
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54
pubmed: 30806709
Mol Genet Metab. 2022 Aug;136(4):324-329
pubmed: 35786528
Arthritis Rheumatol. 2019 May;71(5):829-831
pubmed: 30666809
Metab Brain Dis. 2021 Jun;36(5):859-863
pubmed: 33721182
Ann Rheum Dis. 2016 Dec;75(12):e76
pubmed: 27811148
Mol Genet Metab. 2020 Jun;130(2):153-160
pubmed: 32279991